FDA
-
-
-
-
-
-
-
Lyell begins dosing in phase 3 CAR T-cell trial for lymphoma
-
-
-
-
-
-
-
Lyell Immunopharma acquires CAR T-cell therapy for colorectal cancer
-
-
-
-
-
-
-
Lyell Immunopharma (LYEL) PT Raised to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
-
-
-
-
-
-
-
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
-
-
-
-
-
-
-
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
-
-
-
-
-
-
-
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

